India News | Zydus Receives Final Approval from USFDA to Market Drug Used to Relieve Chest Pain
Get latest articles and stories on India at LatestLY. Zydus Lifesciences Ltd. has received final approval from the United States Food and Drug Administration (USFDA) to market Nitroglycerin Sublingual tablets used to relieve chest pain in people who have certain heart conditions, said the pharmaceutical company on Wednesday.
By Shalini Bhardwaj
New Delhi [India], March 9 (ANI): Zydus Lifesciences Ltd. has received final approval from the United States Food and Drug Administration (USFDA) to market Nitroglycerin Sublingual tablets used to relieve chest pain in people who have certain heart conditions, said the pharmaceutical company on Wednesday.
Also Read | Delhi: Doctors Treat Uzbekistan Woman With Rare Kidney Failure Post Delivery.
As per the statement issued by the company, the tablets are in the strengths of 0.3 mg, 0.4mg and 0.6mg (US RLD: Nitrostat Sublingual Tablets).
"Nitroglycerin Sublingual tablets are used to relieve chest pain (angina) in people who have a certain heart condition (coronary artery disease)," said the company.
Also Read | Madhya Pradesh Budget 2022-23: MP Govt Presents Rs 2,79,237 Crore Budget, No New Taxes Announced.
The company further said that the tablets may also be used before physical activities to help prevent chest pain. Nitroglycerin belongs to a class of drugs known as nitrates.
It stated that the drug will be manufactured at the group's formulation manufacturing facility at SEZ, Ahmedabad.
The group now has 329 approvals and has so far filed over 400 abbreviated new drug applications (ANDAs) since the commencement of the filing process in the financial year 2003-04, added the company statement. (ANI)
(The above story is verified and authored by ANI staff, ANI is South Asia's leading multimedia news agency with over 100 bureaus in India, South Asia and across the globe. ANI brings the latest news on Politics and Current Affairs in India & around the World, Sports, Health, Fitness, Entertainment, & News. The views appearing in the above post do not reflect the opinions of LatestLY)